Benitec Biopharma (BNTC) Consolidated Net Income (2019 - 2025)

Benitec Biopharma has disclosed Consolidated Net Income across 7 years of filings, most recently posting -$12.0 million for Q4 2025.

• Consolidated Net Income for Q4 2025 came in at -$12.0 million, down 773.69% year-over-year; the trailing twelve-month figure through Dec 2025 was -$33.9 million (down 121.11% YoY), and the FY2025 annual result was -$38.5 million, down 78.26% from the prior year.
• Consolidated Net Income came in at -$12.0 million for Q4 2025 at Benitec Biopharma, down from -$8.8 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$1.4 million in Q4 2024 to a low of -$12.0 million in Q4 2025.
• The 5-year median for Consolidated Net Income is -$4.7 million (2022), against an average of -$5.3 million.
• Across the five-year window, Consolidated Net Income surged 80.21% in 2024 and sank 773.69% in 2025, its largest moves.
• Benitec Biopharma's Consolidated Net Income stood at -$4.8 million in 2021, then declined by 15.95% to -$5.6 million in 2022, then decreased by 23.38% to -$6.9 million in 2023, then soared by 80.21% to -$1.4 million in 2024, then sank by 773.69% to -$12.0 million in 2025.
• The last three Consolidated Net Income figures came in at -$12.0 million (Q4 2025), -$8.8 million (Q3 2025), and -$8.8 million (Q2 2025), per Business Quant data.